Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Metastatic bone disease is an important prognostic factor for survival which will in median
be close to two years after first diagnosis of osseous metastases. This open-label study will
investigate the safety and efficacy of zoledronic acid in patients with breast cancer and
minimal residual disease in the bone marrow.